Welcome to our dedicated page for OSR HEALTH news (Ticker: OSRH), a resource for investors and traders seeking the latest updates and insights on OSR HEALTH stock.
OSR Holdings, Inc. (NASDAQ: OSRH) generates news across multiple areas of healthcare and biotechnology, reflecting its role as a global healthcare holding company focused on immuno-oncology, regenerative biologics, and medical device technologies. The company’s news flow often centers on developments at its key subsidiaries, strategic licensing discussions, clinical data updates, and corporate finance activities.
One major stream of OSR Holdings news relates to Vaximm AG, its Swiss-German immuno-oncology subsidiary. Press releases have detailed Vaximm’s proprietary orally administered T-cell vaccination platform, the clinical progress of lead candidate VXM01 targeting VEGFR-2, and negotiations with BCM Europe AG and affiliated investment vehicles for potential global exclusive licensing arrangements. Updates have covered non-binding and binding term sheets, proposed upfront and milestone payment structures, royalty pass-through mechanisms, and plans to obtain independent fairness opinions, providing insight into how OSR Holdings seeks to unlock value from its immunotherapy assets.
Another important category of news involves Woori IO Co., Ltd., a South Korea-based medical-device company focused on noninvasive glucose monitoring. OSR Holdings has issued releases on the signing and approval of a definitive share exchange agreement under which Woori IO becomes a wholly owned subsidiary of its Korean affiliate, as well as on Woori IO’s collaborations with Samsung Electronics on proof-of-concept studies. News items have also summarized pilot study results for the Glucheck blood glucose measurement system conducted with Korea University Guro Hospital, highlighting accuracy, precision, and ISO 15197:2013 compliance.
Investors following OSRH news will also see announcements about virtual investor events, conference presentations, equity financing arrangements, and Nasdaq listing matters, including notices regarding minimum bid price compliance. This dedicated news page allows readers to track OSR Holdings’ evolving portfolio, licensing initiatives, clinical milestones, and capital markets updates in one place, with new items added as the company furnishes press releases and related SEC communications.
OSR Health (NASDAQ:OSRH) is the focus of a new company-sponsored flash report from Emerging Growth Research, highlighting a recently announced Shareholder Loyalty Program built around non-transferable Contingent Value Rights (CVRs). OSRH plans to issue one CVR per share held on an expected record date targeted for July 31, 2026, at no cost to shareholders and subject to legal counsel’s opinion.
The CVRs offer tiered, cumulative share rewards if OSRH’s share price meets thresholds of $2, $3, $4 and $5 at 3, 6, 9 and 12-month observation dates, respectively, potentially delivering up to five additional shares per original share over 12 months. Emerging Growth Research links the program to strategic momentum from OSRH’s $815 million licensing deal with BCM Europe for drug candidate VXM01 and cites 4PL expansion, non-invasive glucose monitoring integration and continued drug development as additional potential growth drivers. Key risks flagged include OSRH’s limited operating history, early-stage programs, expected dilution from an equity line of credit and a protective put option within the BCM Europe deal, plus the possibility of OTC migration if the share price remains below $1.00 by the end of August and the Company maintains its stance against a reverse split.
OSR Health (NASDAQ:OSRH) has received a Nasdaq Staff Delisting Determination dated August 19, 2026 and plans to submit a formal hearing request to the Nasdaq Independent Hearings Panel by August 26, 2026, while a trading suspension is expected on August 26.
According to OSR Health, under its April 2026 VXM01 Global Exclusive License Agreement, the company holds a $15 million Put Option exercisable against BCM Europe AG from October 29, 2026 at $10.00 per share. Management reports ongoing communication with BCM Europe’s Korean end investors regarding option settlement, and states that development at subsidiaries Woori IO and Darnatein will continue alongside preparations for a CVR registration statement.
OSR Health (NASDAQ:OSRH) received a Nasdaq Staff Delisting Determination stating that its common stock and warrants are subject to delisting from The Nasdaq Capital Market for not regaining compliance with the minimum $1.00 bid price requirement under Rule 5550(a)(2) within the allotted periods.
The company plans to request a hearing before the Nasdaq Independent Hearings Panel to appeal. According to OSR Health, OSRH traded about 370 million shares on August 17 and 145 million on August 18, 2026, versus a public float of 18.5 million shares, reaching an intraday high of $0.84 on August 18. Because OSR Health has already used its second 180‑day compliance period, its stock (OSRH) and warrants (OSRHW) are scheduled to be suspended from Nasdaq trading at the open on August 26, 2026, with no automatic stay from a timely hearing request. The company cautions there is no assurance the Panel will grant continued listing or reinstatement.
OSR Health (NASDAQ:OSRH) released a shareholder letter from CEO Peter Hwang addressing the company’s Nasdaq listing status and subsidiary progress. Nasdaq is expected to decide on OSRH’s continued listing around August 18 if its share price does not meet the $1.00 minimum bid requirement.
Hwang reports that two OSR Health subsidiaries have received inbound inquiries for potential out-licensing of their technologies, with one opportunity at a preliminary term sheet negotiation stage and the other at an earlier stage. He emphasizes his role as OSRH’s largest investor, the company’s history of funding cash-burning R&D, and an experienced management team guiding the business through what he calls one of the company’s most difficult years.
OSR Health (NASDAQ:OSRH) issued a clarification regarding its earlier communication about Nasdaq and its Shareholder Loyalty CVR Program. The company stated that a prior description of Nasdaq’s feedback should not be taken as Nasdaq approval or endorsement. Nasdaq’s input was limited to a preliminary, verbal view on mechanical stock price adjustments. OSR Health confirmed the August 14, 2026 record date and indicated that program details and enrollment information remain available on its website.
OSR Health (NASDAQ:OSRH)/b) announced that its subsidiary has completed analysis of two clinical studies of VXM01, an oral DNA vaccine targeting VEGFR-2, in patients with recurrent glioblastoma. The company plans to submit the data for publication in a peer-reviewed journal and to share additional top-line results, including plans for further clinical development, in the coming months.
According to OSR Health, the forthcoming manuscript is expected to show that VXM01, as monotherapy and in combination therapy, was safe and well tolerated, with no dose-limiting toxicities or high-grade treatment-related adverse events. The data reportedly demonstrate successful immune activation against the target, indications of dose-dependent immunologic activity, and biomarker findings consistent with the proposed mechanism of action, supporting VXM01 and OSR’s oral DNA vaccine platform across multiple cancer indications.
OSR Health (NASDAQ:OSRH) announced that, according to a verbal communication from Nasdaq, its Shareholder Loyalty Contingent Value Rights (CVR) program will not trigger any mechanical adjustment to the price of OSRH common stock, either on CVR distribution or when additional shares are delivered to enrolled holders.
Shareholders of record on August 14, 2026/b) who enroll are eligible to receive one CVR per share and may receive additional no-cost shares if defined closing-price thresholds are met at four measurement dates over the following twelve months. OSR Health noted that Nasdaq’s position covers only price-adjustment treatment and is not an endorsement of the program or the stock.
OSR Health (NASDAQ:OSRH) CEO Peter Hwang outlined a proposed Shareholder Loyalty CVR Program designed to grant existing investors up to five additional shares per CVR, potentially increasing their position to six times the original if all four cumulative price and holding-period tiers are met ($2, $3, $4, $5 over 3, 6, 9, 12 months).
The letter highlights VXM01, licensed from Vaximm, with up to $815 million in potential milestones and an independent risk-adjusted NPV of about $94 million. OSR Health also holds a $15 million cash Put Option against BCM Europe AG, exercisable from October 29, 2026. Management notes Woori IO, a noninvasive glucose monitoring portfolio company, as an asset they believe the market has not fully considered. The CVR record date is set for August 14, 2026.
OSR Health (NASDAQ:OSRH) is the focus of a new Emerging Growth Research flash report reaffirming its Buy-Emerging rating and $10.00 12‑month price target. The report centers on a Board‑approved Shareholder Loyalty Program using Contingent Value Rights instead of a reverse stock split.
One CVR per share is planned for holders of record around July 31, 2026, subject to legal review. Tiered share‑price milestones over 12 months could deliver up to five additional shares per original share. The report also highlights the $815 million BCM Europe licensing deal and other potential growth drivers.
OSR Health (NASDAQ:OSRH) announced a Shareholder Loyalty Program using non-transferable Contingent Value Rights (CVRs) granted 1:1 to shareholders of record, tentatively on July 31, 2026. Over 12 months, if OSRH stock hits price tiers from $2–$5 and holders continuously hold, each CVR can deliver up to 5 additional shares, increasing positions up to sixfold. CVRs have no standalone value, are forfeited if shares are sold, and distributions depend on legal review, registration, and other customary conditions.